06Mar/13

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN … – Investor's Business Daily

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN
Investor’s Business Daily
The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall

and more »

06Mar/13

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN … – Financial Post

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN
Financial Post
The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall

and more »

06Mar/13

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN … – Business Wire (press release)

Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN
Business Wire (press release)
The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall

and more »